Federated Hermes’s Viridian Therapeutics VRDN Stock Holding History

Federated Hermes’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Sell	14,238 -654,730	-98%	-$10.5M	﹤0.01%	1477
2026 Q1	$13.1M	Buy	668,968 +252,610	+61%	+$7.5M	0.02%	568
2025 Q4	$13M	Buy	416,358 +416,226	+315,323%	+$11.4M	0.02%	558
2025 Q3	$2.85K	Buy	132 +13	+11%	+$234	﹤0.01%	2001
2025 Q2	$1.66K	Buy	+119	New	+$1.61K	﹤0.01%	1969
2023 Q2	–	Sell	-77,342	Closed	-$1.97M	–	2230
2023 Q1	$1.97M	Buy	77,342 +56,507	+271%	+$1.81M	0.01%	961
2022 Q4	$609K	Buy	+20,835	New	+$480K	﹤0.01%	1301
2020 Q2	–	Sell	-92	Closed	-$1K	–	2384
2020 Q1	$1K	Buy	+92	New	+$1.07K	﹤0.01%	2160

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Federated Hermes's VRDN Position: Q2 2026 in Review

Federated Hermes reduced its Viridian Therapeutics (VRDN) stake by 98% in Q2 2026, selling an estimated $10.5M and leaving 14,238 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #1477.

Federated Hermes first reported a position in VRDN in Q1 2020 and has held it in 8 quarters since. The position peaked at $13.1M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Federated Hermes held 14,238 shares of Viridian Therapeutics worth $262K as of Q2 2026.
Federated Hermes sold 654,730 Viridian Therapeutics shares in Q2 2026, an estimated $10.5M.
Viridian Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1477 holding.
Federated Hermes first reported a position in Viridian Therapeutics in Q1 2020 and has held it in 8 quarters since.
Federated Hermes's Viridian Therapeutics position peaked at $13.1M in Q1 2026.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.